Open Access401A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects
Author(s) -
David E. Griffith,
Christopher M. Rubino,
Jeff Loutit,
Elizabeth E. Morgan,
Dan White,
Michael Dudley
Publication year - 2014
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofu052.267
Subject(s) - medicine , meropenem , tolerability , pharmacokinetics , beta lactamase inhibitors , pharmacology , adverse effect , antibiotics , microbiology and biotechnology , antibiotic resistance , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom